Clinical Trial Update: Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating dabrafenib plus trametinib in BRAF mutation-positive metastatic melanoma with brain metastases has completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Trametinib (trametinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Melanoma and Brain Metastases | Phase 2 | Status: COMPLETED | Results posted: 2019-05-21